Regression of diabetic nephropathy: no dose-response effect of an angiotensin II antagonist (2007)
- Authors:
- USP affiliated authors: FERNANDES, BIANCA HELENA VENTURA - FM ; FANELLI, CAMILLA - FM ; FUJIHARA, CLARICE KAZUE - FM ; ZATZ, ROBERTO - FM
- Unidade: FM
- Subjects: NEFROPATIAS; ANGIOTENSINA II (ANTAGONISTAS E INIBIDORES); RESUMOS (SIMPÓSIOS)
- Language: Inglês
- Imprenta:
- Source:
- Conference titles: Simpósio avanços em pesquisas médicas
-
ABNT
TELES, Flavio et al. Regression of diabetic nephropathy: no dose-response effect of an angiotensin II antagonist. Clinics. São Paulo: Faculdade de Medicina, Universidade de São Paulo. . Acesso em: 24 abr. 2024. , 2007 -
APA
Teles, F., Fernandes, B. H. V., Sena, C. R., Fanelli, C., Poppi, E. P. B., Machado, F. G., et al. (2007). Regression of diabetic nephropathy: no dose-response effect of an angiotensin II antagonist. Clinics. São Paulo: Faculdade de Medicina, Universidade de São Paulo. -
NLM
Teles F, Fernandes BHV, Sena CR, Fanelli C, Poppi EPB, Machado FG, Malheiros DMAC, Fujihara CK, Zatz R. Regression of diabetic nephropathy: no dose-response effect of an angiotensin II antagonist. Clinics. 2007 ; 62 S44.[citado 2024 abr. 24 ] -
Vancouver
Teles F, Fernandes BHV, Sena CR, Fanelli C, Poppi EPB, Machado FG, Malheiros DMAC, Fujihara CK, Zatz R. Regression of diabetic nephropathy: no dose-response effect of an angiotensin II antagonist. Clinics. 2007 ; 62 S44.[citado 2024 abr. 24 ] - Combined losartan and hydrochlorothiazide prevents progression of renal injury in chronic nephropathy resulting from losartan treatment
- Combined Losartan (L) and Hydrocholorothyazide (H) treatment (LH) prevents progression of chronic kidney disease (CKD) resulting from L treatment during lactation (LLac)
- Regressão da nefropatia diabética experimental: Ausência de efeito dose resposta de um antagonista da angiotensina II
- High-dose losartan (L) provides no additional protection in a model of chronic kidney disease (CKD) caused by L treatment during lactation (LLac)
- Renoprotective effect of two dosages of Losartan (L) in a model of crhonic kidney disease (CDK) by nitric oxide inhibition and and salt overload
- Losartan (L) and hydrochlorotiazide (H) association (LH) arrests renal inhury in a model of very advanced chronic kidney disease (CKD)
- Losartan (L) and Hydrochlorothiazide (H)Treatment (LH) arrests renal and cardiac injury in advanced chronic kidney disease by mechanisms not entireky dependent on blood pressure
- Furosemide (F) is less effective than hydroclorothiazide (H) as adjuvant to losartan (L) in arresting the nephropathy associated with the 5/6 renal ablation model (NX)
- Associação terapêutica de losartan (L) e hidroclorotiazida (H) previne progressão da lesão renal em modelo de nefropatia crônica resultante da administração de (L) durante a lactação
- Hydrochlorothiazide and losartan in combination prevent progressive nephropathy in the 5/6 renal ablation model
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
